TL;DR
Multiple findings supporting the potential for LP-184, a novel alkylating agent with three FDA orphan drug designations, to fill this void clinically are reported: strong nanomolar potency; sustained, durable regression of solid tumor xenografts; synthetic lethality with HR defects.
AI-generated by Semantic Scholar
Authors
Aditya Kulkarni, Jianli Zhou, Neha Biyani, Umesh Kathad, Partha P. Banerjee, Shiv Srivastava, Zsombor Prucsi, Kamil Solarczyk, Kishor Bhatia, Reginald B. Ewesuedo, Panna Sharma
